Skip to main
HCA

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare (HCA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 21%
Sell 5%
Strong Sell 0%

Bulls say

HCA Healthcare's financial position remains robust, ending the year with $1.04 billion in cash and $5.78 billion in available credit, coupled with an 8.3% increase in dividends to $0.78 per share. The company's projected EBITDA growth of 7.6% and improved EBITDA margins of 21.1% highlight effective management strategies, particularly in operational efficiencies. Furthermore, HCA's strategic capital expenditure increase to $5.0-$5.5 billion for 2026, aimed at expanding high acuity programs and inpatient capacity, underscores a commitment to enhancing service offerings and driving future growth.

Bears say

HCA Healthcare is anticipating a significant decline in utilization of care, projecting a 30% reduction for the approximately 80%-85% of patients expected to be uninsured, which could negatively impact overall revenue. Additionally, the company forecasts a substantial decrease of $250-$450 million in DPP net benefits for 2026, largely due to the cessation of certain Medicaid programs and a reduction in historical contributions from specific states. Furthermore, the adjusted EBITDA outlook for 2026, estimated at $15.55-$16.45 billion, reflects the presence of headwinds associated with these challenges, indicating potential pressure on profitability.

HCA Healthcare (HCA) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 21% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HCA Healthcare (HCA) Forecast

Analysts have given HCA Healthcare (HCA) a Buy based on their latest research and market trends.

According to 19 analysts, HCA Healthcare (HCA) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $535.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $535.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HCA Healthcare (HCA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.